Clinical efficacy of an extracorporeal granulocyte removal column(G-1) on rheumatoid arthritis: A multicenter clinical study.:<I>A multicenter clinical study</I>
スポンサーリンク
概要
- 論文の詳細を見る
The clinical efficacy of an extracorporeal granulocyte removal column (G-1) was investigated in two groups of patients with rheumatoid arthritis (RA) . Group I (<I>n</I>=85) received a total of 4 apheresis, one apheresis per week ; Group II (<I>n</I>=79) received a total of 8 apheresis, two apheresis per week. In both groups, the duration of each apheresis was 60 minutes, at a flow rate of 30 ml/minute. With respect to safety, 164 cases (patients), with respect to efficacy and usefulness, 143 cases and with respect to maintained effectiveness, 65 eases were assessed and the following results were obtained.<BR>1) Two weeks after the last apheresis, overall improvement was 49.7% ; in Group I, 50.6% ; in Group II, 48.4%. Overall safety was 94.5% ; in Group, 96.5% ; in Group II, 92.4%. Overall usefulness was 49.7% ; in Group I, 50.6% ; in Group II, 48.4%. The results of the two groups were not significantly different.<BR>2) At 12 weeks after the end of the treatment with G-1, the overall maintained effectiveness was 72.3% ; in Group I, 81.6% and in Group II, 59.3% ; indicating continuation of effects for 12 weeks after 4 weeks treatment. In both groups, the effectiveness of G-1 assessed at the conclusion of observations period was statisti-cally significant (<I>p</I> <0.05) .<BR>3) The incidence of adverse events was very low, 3 cases with recovery without interruption of treatment, plus 3 cases of abnormal clinical laboratory tests.<BR>4) The joint symptoms (number of joints with swelling or pain) were reduced by 50% in 67.1% of patients. There was immediate improvement, within one week after the initiation of treatment in 35.7% of patients.<BR>5) There was improvement of anemia and plasma albumin.<BR>The results of this clinical investigation indicate that patients with rheumatoid arthritis can benefit from the apheresis treatment with G-1 to eliminate the granulocytes in part from their peripheral blood and also to reduce joint symptoms in two third of the patients. The G-1 treatment appears to be safe, producing rapid and long lasting clinical effect.
- 日本炎症・再生医学会の論文
日本炎症・再生医学会 | 論文
- 新規キノリノン誘導体TA-270の炎症性気道疾患に対する効果
- Salazosulphapyridine, Predonizolone の好中球機能に及ぼす影響と Sodium ferrous citrate との併用効果についての検討
- Sodium ferrous citrate の好中球機能に及ぼす影響
- Mesalazine(Pentasa) の好中球機能に及ぼす影響と Sodium ferrous citrate(SFC) との併用効果についての検討
- 非ウイルスベクターによる細胞標的法の開発